278,164 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Braidwell LP

Braidwell LP bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 278,164 shares of the company’s stock, valued at approximately $26,473,000. Braidwell LP owned 0.42% of Oruka Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth $28,000. Nykredit A S purchased a new stake in Oruka Therapeutics during the second quarter valued at $29,000. BNP Paribas Financial Markets lifted its holdings in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada lifted its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter worth about $37,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Down 0.5%

Shares of Oruka Therapeutics stock opened at $91.63 on Thursday. The stock’s 50-day simple moving average is $95.11 and its 200-day simple moving average is $69.01. Oruka Therapeutics, Inc. has a 52 week low of $14.66 and a 52 week high of $115.51. The company has a market capitalization of $6.07 billion, a price-to-earnings ratio of -45.14 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, equities analysts expect that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

ORKA has been the subject of a number of recent research reports. Wedbush restated an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. UBS Group raised their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

Insiders Place Their Bets

In other news, Director Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the sale, the director owned 51,326 shares in the company, valued at $3,599,492.38. This trade represents a 30.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 75,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at $84,996,011.40. This trade represents a 7.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 158,116 shares of company stock valued at $13,523,783. 23.49% of the stock is owned by company insiders.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.